drugset / Trial / NCT00928135

Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects

NCT00928135

Phase 1/2 Completed 63 enrolled Joseph Zabner
RandomizedParallel-groupTriple-blindOther

Summary

Cystic fibrosis (CF) lung disease is characterized by chronic bacterial colonization and recurrent infection of the airways. Lowering the airway surface liquid (ASL) salt concentration has been shown to increase activity of salt sensitive antimicrobial peptides. Xylitol is a 5-carbon sugar that can lower the ASL salt concentration, thus enhancing innate immunity. In this study, the investigators propose to test the safety and tolerability of aerosolized xylitol used daily for 2 weeks in subjects with cystic fibrosis. In a pilot, 2-week study, 60 subjects with cystic fibrosis with an FEV1(Forced expiratory volume in 1 second ) \>30% predicted will be randomized to receive aerosolized 7% hypertonic saline (5 ml) or 15% xylitol, (5 ml) twice a day for 14 days. The primary outcomes will be safety as assessed by FEV1 change from baseline, adverse events and respiratory symptom score. Outcomes for trend in efficacy include density of colonization of sputum, time to next exacerbation, sputum cytokines and revised CF quality of life questionnaire.

Timeline

Start
2013-01-22
Primary completion
2018-04-09
Completion
2018-04-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hypertonic saline Unknown 5 ml Other
Comparator Hypertonic saline Unknown 7 % Other
Subject Xylitol Small molecule 5 ml Other
Subject Xylitol Small molecule 15 % Other

Indications